These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38267451)

  • 1. Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study.
    Yi Y; Kwon EJ; Yun G; Park S; Jeong JC; Na KY; Chin HJ; Yoo S; Kim S; Oh TJ; Kim S; Jung CH; Lee H
    Sci Rep; 2024 Jan; 14(1):2081. PubMed ID: 38267451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.
    Kwon S; Kim YC; Park JY; Lee J; An JN; Kim CT; Oh S; Park S; Kim DK; Oh YK; Kim YS; Lim CS; Lee JP
    Diabetes Care; 2020 May; 43(5):948-955. PubMed ID: 32132005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
    Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
    Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriateness of metformin prescription for type 2 diabetes mellitus patients with chronic kidney disease (Stages 3-5).
    Ramachandran M; Loi B; Mat Ariff N; Ng OC; Zahari Sham SY; Thambiah SC; Samsudin IN
    Malays J Pathol; 2020 Apr; 42(1):71-76. PubMed ID: 32342933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective cohort study of clinical characteristics and outcomes of type 2 diabetic patients with kidney disease.
    He X; Deng Y; Tian B; Zhao Y; Han M; Cai Y
    PeerJ; 2024; 12():e16915. PubMed ID: 38390389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
    Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; Eckardt KU; McMurray JJV; Weinrauch LA; Liu J; Claggett B; Lewis EF; Pfeffer MA
    Diabetes Obes Metab; 2019 May; 21(5):1199-1208. PubMed ID: 30672083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function markers and metformin eligibility.
    Tavares Bello C; Castro Fonseca R; Sousa Santos F; Sequeira Duarte J; Azinheira J; Vasconcelos C
    Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease.
    Rhee JJ; Han J; Montez-Rath ME; Kim SH; Cullen MR; Stafford RS; Winkelmayer WC; Chertow GM
    J Diabetes Complications; 2019 Nov; 33(11):107423. PubMed ID: 31537413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study.
    Chan GC; Ng JK; Chow KM; Szeto CC
    Diabetes Res Clin Pract; 2023 Jan; 195():110200. PubMed ID: 36481225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis.
    Dimnjaković J; Buble T; Ivanko P; Poljičanin T; Karanović Štambuk S; Brborović H; Brborović O
    PLoS One; 2024; 19(3):e0301056. PubMed ID: 38536830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients.
    Fung CS; Wan EY; Wong CK; Jiao F; Chan AK
    Cardiovasc Diabetol; 2015 Oct; 14():137. PubMed ID: 26453464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study.
    Alvarez CA; Halm EA; Pugh MJV; McGuire DK; Hennessy S; Miller RT; Lingvay I; Vouri SM; Zullo AR; Yang H; Chansard M; Mortensen EM
    Endocrinol Diabetes Metab; 2021 Jan; 4(1):e00170. PubMed ID: 33532612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinico-pathological features of diabetic and non-diabetic renal diseases in type 2 diabetic patients: a retrospective study from a 10-year experience in a single center.
    Sun Y; Ren Y; Lan P; Yu X; Feng J; Hao D; Xie L
    Int Urol Nephrol; 2023 Sep; 55(9):2303-2312. PubMed ID: 36879071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2 diabetes mellitus management in patients with chronic kidney disease: an update.
    Kleinaki Z; Kapnisi S; Theodorelou-Charitou SA; Nikas IP; Paschou SA
    Hormones (Athens); 2020 Dec; 19(4):467-476. PubMed ID: 32500461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
    Awal HB; Nandula SR; Domingues CC; Dore FJ; Kundu N; Brichacek B; Fakhri M; Elzarki A; Ahmadi N; Safai S; Fosso M; Amdur RL; Sen S
    Cardiovasc Diabetol; 2020 Jun; 19(1):72. PubMed ID: 32493344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.
    Clegg LE; Jing Y; Penland RC; Boulton DW; Hernandez AF; Holman RR; Vora J
    Diabetes Obes Metab; 2021 May; 23(5):1101-1110. PubMed ID: 33394543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey.
    Gor D; Gerber BS; Walton SM; Lee TA; Nutescu EA; Touchette DR
    J Diabetes; 2020 May; 12(5):385-395. PubMed ID: 31652390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.